Prognostic and predictive implications of HER2 status for breast cancer patients

European Journal of Oncology Nursing

Volumn 4, Issue , 2000, Pages 10-17

  Thomas, Elisabeth ^a   Berner, Gisela ^a  

^a Robert Janker Klinik   (Germany)

Author keywords

Breast cancer; Chemotherapy; Hormone therapy; Human epidermal growth factor receptor 2; Prognosis; Prognostic factors

Indexed keywords

EID: 0347507159     PISSN: 14623889     EISSN: None     Source Type: Journal    
DOI: 10.1054/ejon.2000.0073     Document Type: Article

References (66)

1. Ali IU, Campbell G, Lidereau R, Callahan R (1988) Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast cancer. Oncogene Research 3: 139-146
2. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL (1992a) HER-2/ neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. Journal of Clinical Oncology 10: 599-605
3. Allred DC, Clark GM, Molina R (1992b) Overexpression of HER-2/neu and its relationship with other prognostic factors changed during progression of in-situ to invasive breast cancer. Human Pathology 23: 974-979
4. Ambler N, Rumsey N, Harcourt D, Khan F, Cawthorn S, Barker J (1999) Specialist nurse counsellor interventions at the time of diagnosis of breast cancer: comparing 'advocacy' with a conventional approach. Journal of Advanced Nursing 29: 445-453
5. American Society of Clinical Oncology (1998) 1997 update of recommendations for the use of tumour markers in breast and colorectal cancer. Journal of Clinical Oncology 16: 793-795
6. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KPH, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D, for the Toronto Breast Cancer Study Group (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Journal of Clinical Oncology 16: 1340-1349
7. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JFR (1995) Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. British Journal of Cancer 72: 1259-1266
8. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR (1992) Overexpression of the c-erbB-2 oncogene: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance. European Journal of Cancer 28: 644-648
9. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment 24: 85-95
10. Berns EMJJ, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG (1995) Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11-18
11. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S (1993) Prognostic significance of c-erbB-2 expression in node negative breast cancer. British Journal of Cancer 67: 625-629
12. Bianco AR, De Laurentiis M, Carlomagno C, Lauria R, Petrella G, Panico L, Pettinato G, Perrone F, Gallo C, Marinelli A, De Placido S (1998) 20 year update of the Naples Gun trial of adjuvant breast cancer therapy: evidence of interaction between c-erbB-2 expression and tamoxifen efficacy. Proceedings of the American Society of Clinical Oncology 17: 97A
13. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL (1990) HER-2/ neu amplification predicts poor survival in node-positive breast cancer. Cancer Research 50: 4332-4337
14. Bull AA, Meyerowitz BE, Hart S, Mosconi P. Apolone G, Liberati A (1999) Quality of life in women with recurrent breast cancer. Breast Cancer Research and Treatment 54: 47-57
15. Cameron DA, Leonard RCF (1999) Re: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal of the National Cancer Institute 91: 728-729
16. Chazin VR, Kaleko M, Miller AD, Slamon DJ (1992) Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor. Oncogene 7: 1859-1866
17. Clahsen PC, van de velde CJH, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ (1998) P53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. Journal of Clinical Oncology 16: 470-479
18. Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Research 51: 944-948
19. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS (1983) Progesterone receptors as a prognostic factor in stage II breast cancer. New England Journal of Medicine 309: 1343-1347
20. Cook NF (1999) Self-concept and cancer: understanding the nursing role. British Journal of Nursing 8: 318-324
21. Devine EC, Westlake SK (1995) The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies. Oncology Nursing Forum 22: 1369-1381
22. Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, Lennard TJ, Angus B, Home CH (1991) Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. Journal of Pathology 163: 105-110
23. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942
24. Elledge RM, Green S, Ciocca D, Pugh R, Allred C, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK (1998) HER-2 expression and response to tamoxifen in oestrogen receptor positive breast cancer: a Southwest Oncology Study Group study. Clinical Cancer Research 4: 7-12
25. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jäger W (1997) Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-negative breast cancer patients. Breast Cancer Research and Treatment 42: 87-95
26. Ferrario R (1999) Nurse's counselling role in cancer. European Journal of Cancer 35(Suppl 4): S8 [abstract 9]
27. Giai M, Roagna R, Ponzone R, de Bortoli M, Dati C, Sismondi P (1994) Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Research 14: 1441-1450
28. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG (1991) c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. British Journal of Cancer 63: 434-438
29. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhgan R, Styles J, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Büki K, Castiglione M, Collins J, Lindtner J, Senn H-J (1992) Prognostic importance of c-erbB-2 expression in breast cancer. Journal of Clinical Oncology 10: 1049-1056
30. Haffty BG, Brown F, Carter D, Flynn S (1996) Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. International Journal of Radiation Oncology, Biology and Physics 35: 751-757
31. Harbeck N, Ross JS, Yurdseven S, Dettmar P, Polcher M, Kühn W, Ulm K, Graeff H, Schmitt M (1999) NER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. International Journal of Oncology 14: 663-671
32. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW (1999) Overexpression of c-erbE2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. British Journal of Cancer 79: 1220-1226
33. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/ HER-2 and its role in cancer. Biochimica et Biophysica Acta 1198: 165-184
34. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A (1995) Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. Journal of Clinical Oncology 13: 1129-1135
35. Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, Sawyer WT (1999) Perception of chemotherapy side effects: Cancer versus noncancer patients. Cancer Practice 7: 59-65
36. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM (1996) Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. British Journal of Cancer 74: 1458-1465
37. Ménard S, Valagussa S, Pilotti E, Biganzoli E, Boracchi P, Casalini P, Tomasic G, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G (1999) Benefit of CMF treatment in lymph-node positive breast cancer overexpressing HER2. Proceedings of the American Society of Clinical Oncology 18: 69a
38. Moreno A, Lloveras B, Figueras A, Escobedo A, Ramon JM, Sierra A, Fabra A (1997) Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. Modern Pathology 10: 1088-1092
39. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman R, Wood WC, Barcos M, Henderson IC (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New England Journal of Medicine 330: 1260-1266
40. Muss H, Berry D, Thor A, Liu E, Edgerton S, Budman D, Wood W, Henderson C, Cirrincione C, Hayes D, Barcos M, Norton L (1999) Lack of interaction of tamoxifen (T) use and ErbB-2/HER-2/neu (H) expression in CALGB 8541: a randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node-positive primary breast cancer (BC). Proceedings of the American Society of Clinical Oncology 18: 68a
41. Newby JC, Johnston SRD, Smith IE, Dowsett M (1997) Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clinical Cancer Research 3: 1643-1651
42. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JFR, Ellis IO, Blamey RW (1993) Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. European Journal of Cancer 29A: 1018-1023
43. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius V-M (1997) Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. British Journal of Cancer 76: 917-922
44. Norton L (1999) Kinetic concepts in the systemic drug therapy of breast cancer. Seminars in Oncology 26(Suppl 12): 11-20
45. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. Journal of Clinical Oncology 8: 103-112
46. Paik S, Bryant J, Park C, Fisher B, Tan-Chui E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N (1998) erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. Journal of the National Cancer Institute 90: 1361-1370
47. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446
48. Plunkett TA, Houston SJ, Rubens RD, Miles DW (1998) c-erbB-2 is a market of resistance to endocrine therapy in advanced breast cancer. Proceedings of the American Society of Clinical Oncology 17: 103A
49. Porter H (1999) The concept of hope and its relevance to the cancer setting. European Journal of Cancer 35(Suppl 4): S31 [abstract 97]
50. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou J-Y, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology 15: 2894-2904
51. Ravdin PM, Green S, Albain V, Boucher V, Ingle J, Pritchard K, Shepard L, Davidson N, Hayes DF, Clark GM, Martino S, Osborne CK, Allred DC (1998) Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. Proceedings of the American Society of Clinical Oncology 17: 97a
52. Ream E, Richardson A (1999) Beating fatigue: Evaluation of a programme developed to assist patients receiving chemotherapy cope with fatigue. European Journal of Cancer 35(Suppl 4): S30 [abstract 91]
53. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428
54. Rozan S, Vincent-Salmon A, Zafrani B, Validire P, De Cremoux P, Bernoux A, Nieruchalski M, Fourquet A, Clough K, Dieras V, Pouillart P, Sastre-Garau X (1998) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. International Journal of Cancer (Predictive Oncology) 79: 27-33
55. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P for the South Australian Breast Cancer Study Group (1993) Clinical significance of HER-2/ neu oncogene amplification in primary breast cancer. Journal of Clinical Oncology 11: 1936-1942
56. Shapiro TJ, Clark PM (1995) Breast cancer: what the primary care provider needs to know. Nurse Practitioner 20: 39-42
57. Sjögren S, Inganäs M, Lindgren A, Holmberg L, Bergh J (1998) Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. Journal of Clinical Oncology 16: 462-469
58. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
59. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712
60. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET (1998) erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal of the National Cancer Institute 90: 1346-1360
61. Untch M, Thomssen C, Kahlert D et al (1998) Lack of c-erbB-2 overexpression predicts better response to dose intensification of anthracycline-based chemotherapy in high-risk breast cancer. Abstract no. 110 presented at the San Antonio Breast Cancer Conference, 12-15 December 1998
62. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. New England Journal of Medicine 319: 1239-1245
63. Wright C, Nicholson S, Angus B Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH (1992) Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. British Journal of Cancer 65:118-121
64. Xing WR, Gilchrist KW, Harris CP, Samson W, Meisner LF (1996) FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Research and Treatment 39: 203-212
65. Yamauchi H, O'Neil A, Gelman R, Carney W, Tenney DY, Hösch S, Hayes DF (1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/neu protein. Journal of Clinical Oncology 15: 2518-2525
66. Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P, Sastre-Garau X (1994) Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Seminars in Diagnostic Pathology 11: 208-214